Summarized by Masters of Longevity from BioSpace - Funding.
Commit closed $60 million to fund IND-enabling work and clinic entry.

Key Takeaways
- Commit closed $60 million seed financing led by Ackermans & van Haaren.
- Proceeds will fund IND-enabling activities and an IND filing.
- COM002 is a dual-targeting BiCE for cancer and autoimmune indications.



